PE20220166A1 - Compuestos, composiciones y metodos para el tratamiento de enfermedad - Google Patents

Compuestos, composiciones y metodos para el tratamiento de enfermedad

Info

Publication number
PE20220166A1
PE20220166A1 PE2021001442A PE2021001442A PE20220166A1 PE 20220166 A1 PE20220166 A1 PE 20220166A1 PE 2021001442 A PE2021001442 A PE 2021001442A PE 2021001442 A PE2021001442 A PE 2021001442A PE 20220166 A1 PE20220166 A1 PE 20220166A1
Authority
PE
Peru
Prior art keywords
treatment
alkyl
compounds
disease
compositions
Prior art date
Application number
PE2021001442A
Other languages
English (en)
Inventor
Radhakrishnan P Iyer
Seetharamaiyer Padmanabhan
Subramanian Baskaran
Anjaneyulu Sheri
Dillon Cleary
Ron Mastrolia
Shenghua Zhou
Sreerupa Challa
Rayomand H Gimi
Vishal Nair
Leena Praba Suppiah
Original Assignee
F Star Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Therapeutics Inc filed Critical F Star Therapeutics Inc
Publication of PE20220166A1 publication Critical patent/PE20220166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a un compuesto de formula (I) donde: M es Cl o F; Z es Cl, SR1, SO2R1 o N(R1)(R2); R1 y R2 son cada uno independientemente H o alquilo; R3 es H, alquilo, metilo, haloalquilo, clorometilo, alquoxialquilo, entre otros; L1 es alquilenilo C7-C15, opcionalmente donde un carbono de L1 esta reemplazado por heterociclilo, oxigeno o N, o heteroalquilenilo C11; cada R4 es independientemente halo, CN, CF3, SR7, SOR7, SO2R7, SO2N(R7)(R8), OR7, NHCOR7, NHSO2R7, NHCONHR7, entre otros. Un compuesto seleccionado es 2-cloro-7-(16-carbometoxihexadecil)purina, 5-(16-carbometoxihexdecil)-2,4-dicloropirrolo[3,2-d]pirimidina. Dichos compuestos inhiben la expresion de un receptor de reconocimiento de patrones (PRR) tal como STING. Tambien refiere a una composicion farmaceutica que los comprende, siendo utiles para el tratamiento de un trastorno inflamatorio o una enfermedad proliferativa, tal como el cancer.
PE2021001442A 2019-03-05 2020-03-05 Compuestos, composiciones y metodos para el tratamiento de enfermedad PE20220166A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814025P 2019-03-05 2019-03-05
US201962879178P 2019-07-26 2019-07-26
PCT/US2020/021120 WO2020181050A1 (en) 2019-03-05 2020-03-05 Compounds, compositions, and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
PE20220166A1 true PE20220166A1 (es) 2022-01-28

Family

ID=72338059

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001442A PE20220166A1 (es) 2019-03-05 2020-03-05 Compuestos, composiciones y metodos para el tratamiento de enfermedad

Country Status (20)

Country Link
US (1) US20220168309A1 (es)
EP (1) EP3934652A4 (es)
JP (1) JP2022525010A (es)
KR (1) KR20210135544A (es)
CN (1) CN113645977A (es)
AU (1) AU2020232761A1 (es)
BR (1) BR112021017583A2 (es)
CA (1) CA3131620A1 (es)
CL (1) CL2021002294A1 (es)
CO (1) CO2021012586A2 (es)
CR (1) CR20210508A (es)
DO (1) DOP2021000184A (es)
EC (1) ECSP21073266A (es)
IL (1) IL285782A (es)
JO (1) JOP20210244A1 (es)
MA (1) MA55214A (es)
MX (1) MX2021010701A (es)
PE (1) PE20220166A1 (es)
SG (1) SG11202109452SA (es)
WO (1) WO2020181050A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3860998T3 (da) 2018-10-05 2024-03-25 Annapurna Bio Inc Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2022034474A1 (en) * 2020-08-10 2022-02-17 Novartis Ag Treatments for retinal degenerative diseases
EP4225742A1 (en) 2020-10-05 2023-08-16 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
CN114478715B (zh) * 2020-10-26 2023-12-22 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达s2结构域蛋白的新型冠状病毒疫苗递呈系统及其应用
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
WO2022266711A1 (en) * 2021-06-23 2022-12-29 Aculeus Therapeutics Pty Ltd Substituted amidobenzimidazole dimers as sting modulators
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN115624616B (zh) * 2022-12-21 2023-03-14 上海市东方医院（同济大学附属东方医院） 接头蛋白pinch在诊断血管发育异常相关疾病中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
DK1401837T3 (da) * 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
EP2324044A4 (en) * 2008-08-04 2012-04-25 Univ Miami STING (INTERFERON GENE STIMULATOR), A REGULATOR OF INDIAN IMMUNE RESPONSES
CN106414446A (zh) * 2014-03-13 2017-02-15 新加坡科技研究局 基于稠合嘧啶的异羟肟酸盐衍生物
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds

Also Published As

Publication number Publication date
JP2022525010A (ja) 2022-05-11
BR112021017583A2 (pt) 2021-11-09
IL285782A (en) 2021-10-31
CA3131620A1 (en) 2020-09-10
MX2021010701A (es) 2022-02-21
AU2020232761A1 (en) 2021-10-21
CR20210508A (es) 2022-03-11
EP3934652A1 (en) 2022-01-12
CN113645977A (zh) 2021-11-12
CL2021002294A1 (es) 2022-04-01
DOP2021000184A (es) 2021-12-15
ECSP21073266A (es) 2021-11-30
US20220168309A1 (en) 2022-06-02
WO2020181050A1 (en) 2020-09-10
EP3934652A4 (en) 2022-12-07
CO2021012586A2 (es) 2021-10-20
JOP20210244A1 (ar) 2023-01-30
MA55214A (fr) 2022-01-12
SG11202109452SA (en) 2021-09-29
KR20210135544A (ko) 2021-11-15

Similar Documents

Publication Publication Date Title
PE20220166A1 (es) Compuestos, composiciones y metodos para el tratamiento de enfermedad
PE20161101A1 (es) Derivados de heterociclos biciclicos condensados sustituidos con 2-(het) arilo como agentes para combatir parasitos
PE20170325A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll
PE20170679A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
CY1123533T1 (el) Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20191817A1 (es) Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
UY36101A (es) Herbicidas de piridazinona
PE20170682A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CO6361933A2 (es) Pirazoles fungicidas
PE20181487A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO6220878A2 (es) Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20160026A1 (es) Compuestos heterociclicos como agentes para control de plagas
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
AR098171A1 (es) Piridinilimidazolonas como herbicidas
ECSP088926A (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina
PE20170333A1 (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados